治疗复发/难治性多发性骨髓瘤药物——伊基奥仑赛  

The treatment of relapsed or refractory multiple myeloma——equecabtagene autoleucel

作　　者：胡丁元 门芳 方翼[1] HU Dingyuan;MEN Fang;FANG Yi(Clinical Trial Institution,People's Hospital of Peking University,Beijing 100044,China)

机构地区：[1]北京大学人民医院临床试验机构,北京100044

出　　处：《临床药物治疗杂志》2024年第12期11-15,共5页Clinical Medication Journal

摘　　要：伊基奥仑赛是一种针对B细胞成熟抗原的嵌合抗原受体T细胞疗法,以慢病毒为基因载体转染自体T细胞。2023年6月30日,国家药品监督管理局批准伊基奥仑赛上市,用于治疗既往经过至少三线治疗后进展(至少使用过1种蛋白酶体抑制剂及免疫抑制剂)的复发/难治性多发性骨髓瘤成人患者。本文总结了伊基奥仑赛的发展过程,并对药理作用、药动学、临床疗效、安全性、用法用量及最新研究进展等进行综述,旨在为细胞疗法的药物开发和多发性骨髓瘤患者的临床用药提供参考。Equecabtagene autoleucel is a chimeric antigen receptor T cell therapy targeting B cell maturation antigen.Lentivirus is used as a gene vector to transfect autologous T cells.On June 30,2023,National Medical Products Administration approved the marketing of equecabtagene autoleucel for the treatment of adults with relapsed or refractory multiple myeloma who have progressed after 3 or more lines of therapy(receiving more than one proteasome inhibitor and an immunomodulator).This article summarize the development milestones of equecabtagene autoleucel,and its mechanism of action,pharmacokinetics,clinical efficacy,safety,usage and dosage as well as the latest research progress,in order to provide reference for the development of cell therapy drugs and the clinical use of multiple myeloma patients.

关 键 词：伊基奥仑赛 多发性骨髓瘤 嵌合抗原受体T细胞疗法 B细胞成熟抗原 

分 类 号：R979.1[医药卫生—药品]